Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03451916 · ClinicalTrials.gov registry record · Phase 3
Treatment of Muscle Injury Following Arthroplasty for Hip Fracture (HF)
A Phase 3 study, sponsored by Pluristem.
- Completed
- Registry status
- Phase 3
- Development phase
- 240
- Enrollment target
NCT03451916 is a Phase 3 study that has completed, run by Pluristem. The registered enrollment target is 240 participants.
The verdict
NCT03451916, a Phase 3 study, has completed, sponsored by Pluristem.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 240 participants
- Enrollment target
Study Summary
The objectives of this study are to assess the efficacy, safety, and tolerability of PLX-PAD intramuscular administration for the treatment of muscle injury following arthroplasty for HF.
Interventions
- DRUG Placebo
- DRUG PLX-PAD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2018-07-26 |
| Est. Completion | 2023-09-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03451916
The ClinicalTrials.gov registry entry for NCT03451916 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pluristem, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03451916 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03451916 about?
NCT03451916 is a clinical study titled "Treatment of Muscle Injury Following Arthroplasty for Hip Fracture (HF)". The objectives of this study are to assess the efficacy, safety, and tolerability of PLX-PAD intramuscular administration for the treatment of muscle injury following arthroplasty for HF.
What is the current status of trial NCT03451916?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 240 participants. The study started on 2018-07-26. Estimated completion is 2023-09-06.
What interventions are being tested in trial NCT03451916?
The interventions under investigation include: Placebo (DRUG), PLX-PAD (DRUG).
Who is sponsoring clinical trial NCT03451916?
This trial is sponsored by Pluristem, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.